Navigation Links
Draft National Policy on Sight-saving Drugs unacceptable

Restricting use of drugs for macular degeneration to patients who have already gone blind in one eye is unacceptable concludes the July issue of Drug and Therapeutics Bulletin (DTB).

But that is what the National Institute for Health and Clinical Excellence (NICE), the body responsible for guiding the NHS on which treatments to use, is proposing.

Ranibizumab (Lucentis) and pegaptanib (Macugen) are licensed in the UK for the treatment of neovascular (wet) age-related macular degeneration. A third drug bevacizumab (Avastin) is also used, but not licensed for the condition.

In wet age-related macular degeneration, in which fine central vision is progressively lost, new blood vessels grow beneath the retina, a process stimulated by vascular endothelial growth factor (VEGF). All three drugs potentially block the effects of VEGF.

Wet age-related macular degeneration is the third most common cause of blindness worldwide. It affects around 2.3% of over-65s in Europe. In the UK around 26,000 people develop it each year and 245,000 are blind or visually impaired because of it.

After a thorough examination of published clinical trial data, DTB concludes that there is good evidence that both ranibizumab and pegaptanib prevent further deterioration in vision in most patients. Ranibizumab improved vision in a third.

The NICE draft guidance on use of ranibizumab and pegaptanib was published in June. It recommends ranibizumab for only about 20 per cent of patients with wet age-related macular degeneration, restricting its use to those in whom both eyes are affected and then to the better seeing eye.

Final guidance is due in September.

DTB says: We believe that policies that dictate that patients must go blind in one eye before being given treatment for the other are unacceptable.

It continues: Pegaptanib and ranibizumab need to be made available for use thr oughout the NHS, as is the case in Scotland. In the absence of such national arrangements elsewhere in the UK, NHS commissioners need to work with local clinicians to ensure that the benefits of these drugs are made available to as many patients as possible.

NICE has not issued draft guidance on bevacizumab, but many primary care trusts recommend its use because it is cheaper than pegaptanib and ranibizumab.

DTB says that bevacizumab might provide a lower cost alternative, but cautions that there is as yet no robust evidence of its safety and effectiveness in the treatment of macular degeneration. Therefore, we cannot recommend such use outside of clinical trials.


'"/>




Related medicine news :

1. OPPI Opposes Draft National Pharmaceuticals Policy
2. Smoking Ban Draft Is Put For Consultation
3. Kerala Drafts a New Health Tourism Policy
4. National Lung Study in the process
5. Indian Nationals with Foreign Medical Degrees can now practice in India
6. Hepatitis B Vaccine To Be Included In National Immunization Programme
7. UK Govt Says On Course For National Chlamydia Screening
8. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
9. India extends National TB Control Program
10. President and Founder of National Obesity Forum Resigns
11. Hwang Woo Suk Suspended By Seoul National University
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at www.diabetesscholars.org ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
Breaking Medicine Technology: